MULTIPLE MYELOMA (MM) - Celgene
Area of Research Phase 1 Phase 2 Phase 3 Post-Approval Research MULTIPLE MYELOMA (MM). REVLIMID (lenalidomide) . Relapsed/refractory . . . . . . . . . . . . . . . . . . . . . . . . . . . . Newly diagnosed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Maintenance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . POMALYST /IMNOVID (US/EU). . (pomalidomide) Relapsed/refractory . . . . . . . . . . . . . . . . . . . . . . . . . . . . THALOMID /Thalidomide Celgene . (US/EU) (thalidomide) Newly diagnosed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IMFINZI (durvalumab) a Relapsed/refractory, newly diagnosed* . . . . . . . . . . . . . . CC-122.
Area of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr LYMPHOMA REVLIMID® (lenalidomide) Mantle cell lymphoma: Relapsed/refractory . . . . . . . . . .
Download MULTIPLE MYELOMA (MM) - Celgene
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: